Abstract
Infections represent a well-known complication of antineoplastic chemotherapy that may cause delay of treatment, with alteration of the antineoplastic program and dose-intensity, or even the death of a patient that could heal from his/her neoplasia. Bacterial infections are a major cause of morbidity and mortality in patients who are neutropenic following chemotherapy for malignancy. Therefore a program of antibiotic prophylaxis for febrile neutropenia may be considered in the management strategy of cancer patients.
Highlights
Elio Castagnola ods has been studied only in one, very questionable clinical trial in adults solid tumors
The lower N the number need to treat (NNT), the higher is the probability that prochemotherapy in acute leukemia/non-Hodgkin lymphoma and the level of neutropenia at onset in solid tumors, with no effect estimated for antibacterial prophylaxis in both cases.[9]
Data from a pediatric epidemiological study clearly show that the widespread use of antibacterial prophylaxis causes ecological changes, with acquisition of resistant pathogens in patients who did not receive antibiotics for preventing febrile neutropenia.[19]
Summary
Elio Castagnola ods has been studied only in one, very questionable clinical trial in adults solid tumors
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call